← Back to guidelines
Cardiology18 papers

Right-sided Staphylococcus aureus endocarditis

Last edited: 23 days ago

Overview

Right-sided Staphylococcus aureus endocarditis (RSAE) primarily affects the tricuspid valve and is often associated with intravenous drug use, leading to significant morbidity and mortality 13.

Diagnosis

  • Clinical Presentation: Fever, signs of heart failure, and systemic emboli 13.
  • Laboratory Tests: Blood cultures positive for S. aureus, elevated inflammatory markers 1.
  • Imaging: Echocardiography essential for diagnosis, showing vegetations or valve dysfunction 1.
  • Pleural Effusions: Common, often exudative, serosanguineous, or bloody; empyema rare 2.
  • Management

  • First-Line Treatment:
  • - MSSA: Antistaphylococcal penicillins (e.g., nafcillin) 1. - MRSA: Vancomycin; Linezolid for severe cases but with caution due to long-term safety concerns 1.
  • Adjunctive Treatments:
  • - Daptomycin: Effective and well-tolerated for both MSSA and MRSA bacteremia, including RSAE 1. - Combination Therapy: Vancomycin + rifampicin effective in neonatal cases 4.
  • Surgical Intervention:
  • - Tricuspid Valvulectomy: Considered in refractory cases; prosthetic valve insertion may be needed later 3.

    Special Populations

  • Pediatrics: Combination of vancomycin and rifampicin successfully treated MRSA endocarditis in a newborn 4.
  • Comorbidities: Intravenous drug addiction significantly impacts prognosis and recurrence rates 3.
  • Key Recommendations

  • Primary Therapy Selection: Use antistaphylococcal penicillins for MSSA and vancomycin for MRSA endocarditis (Evidence: Strong 1).
  • Consider Daptomycin: For severe MRSA cases, daptomycin can be an effective alternative (Evidence: Moderate 1).
  • Surgical Management: Tricuspid valvulectomy without valve replacement may be considered in drug-addicted patients with intractable RSAE, with close monitoring for heart failure progression (Evidence: Expert opinion 3).
  • References

    1 Drees M, Boucher H. New agents for Staphylococcus aureus endocarditis. Current opinion in infectious diseases 2006. link 2 Sexauer WP, Quezado Z, Lippmann ML, Goldberg SK. Pleural effusions in right-sided endocarditis: characteristics and pathophysiology. Southern medical journal 1992. link 3 Arbulu A, Holmes RJ, Asfaw I. Tricuspid valvulectomy without replacement. Twenty years' experience. The Journal of thoracic and cardiovascular surgery 1991. link 4 Prandstraller D, Marata AM, Picchio FM. Staphylococcus aureus endocarditis in a newborn with transposition of the great arteries: successful treatment. International journal of cardiology 1987. link90206-3)

    Original source

    1. [1]
      New agents for Staphylococcus aureus endocarditis.Drees M, Boucher H Current opinion in infectious diseases (2006)
    2. [2]
      Pleural effusions in right-sided endocarditis: characteristics and pathophysiology.Sexauer WP, Quezado Z, Lippmann ML, Goldberg SK Southern medical journal (1992)
    3. [3]
      Tricuspid valvulectomy without replacement. Twenty years' experience.Arbulu A, Holmes RJ, Asfaw I The Journal of thoracic and cardiovascular surgery (1991)
    4. [4]
      Staphylococcus aureus endocarditis in a newborn with transposition of the great arteries: successful treatment.Prandstraller D, Marata AM, Picchio FM International journal of cardiology (1987)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG